The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.

ABSTRACT:

Background

Despite the availability of hundreds of cancer drugs, there is insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor cell populations of glioblastoma (GBM).

Results

The PKIS of 357 compounds was initially evaluated in 15 different GSC lines which then led to a more focused screening of the 21 most highly active compounds in 11 unique GSC lines using HTS screening for cell viability. We further validated the HTS result with the second-generation PLK1 inhibitor volasertib as a single agent and in combination with ionizing radiation (IR). In vitro studies showed that volasertib inhibited cell viability, and high levels of the anti-apoptotic protein Bcl-xL expression were highly correlated with volasertib resistance. Volasertib s

SUBMITTER: Dong J 

PROVIDER: S-EPMC5828226 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature